IMM · ASX

Immutep Ltd (ASX:IMM)

AU$0.3

 0.01 (3.39%)
ASX:Live
10/10/2025 04:10:04 PM
Near Resistance Hammer Bullish HALO Ords HALO Consensus Value GROWTH AUS +4
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

IMM Overview

IMM Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Strong

About IMM

Website

Immutep Ltd

Telephone

61.2.8315.7003

Address

Level 32, Suite 32.07 264 George Street Australia Square Sydney, New South Wales (NSW) 2000

Description

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

IMM Price Chart

Key Stats

Market Cap

AU$434.22M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.22 - 0.38

Trade Value (12mth)

AU$214,286.00

1 week

7.27%

1 month

25.53%

YTD

-16.9%

1 year

-7.81%

All time high

4.07

Key Fundamentals

EPS 3 yr Growth

14.10%

EBITDA Margin

N/A

Operating Cashflow

-$62m

Free Cash Flow Return

-37.10%

ROIC

-36.70%

Interest Coverage

-1,825.00

Quick Ratio

11.70

Other Data

Shares on Issue (Fully Dilluted)

1457m

HALO Sector

Healthcare

Next Company Report Date

02-Sep-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.71

IMM Announcements

Latest Announcements

Date Announcements

09 October 25

TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC

×

TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC

08 October 25

Change of Director's Interest Notice - M Voigt

×

Change of Director's Interest Notice - M Voigt

08 October 25

Change of Director's Interest Notice - F Triebel

×

Change of Director's Interest Notice - F Triebel

08 October 25

Change of Director's Interest Notice - P Meyers

×

Change of Director's Interest Notice - P Meyers

01 October 25

Application for quotation of securities - IMM

×

Application for quotation of securities - IMM

22 September 25

New investigator-initiated Phase II trial for Efti

×

New investigator-initiated Phase II trial for Efti

12 September 25

Becoming a substantial holder

×

Becoming a substantial holder

08 September 25

EFTISARC-NEO data accepted for oral presentation at CTOS

×

EFTISARC-NEO data accepted for oral presentation at CTOS

29 August 25

Appendix 4E & 2025 Full Year Statutory Accounts

×

Appendix 4E & 2025 Full Year Statutory Accounts

05 August 25

FDA feedback received for head & neck cancer in CPS below 1

×

FDA feedback received for head & neck cancer in CPS below 1

30 July 25

Immutep Quarterly Activities Report and Appendix 4C

×

Immutep Quarterly Activities Report and Appendix 4C

29 July 25

TACTI-004 trial in progress poster to be presented at WCLC

×

TACTI-004 trial in progress poster to be presented at WCLC

28 July 25

Abstracts Accepted for Presentation at ESMO Congress 2025

×

Abstracts Accepted for Presentation at ESMO Congress 2025

25 July 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

23 July 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

18 July 25

Application for quotation of securities - IMM

×

Application for quotation of securities - IMM

18 July 25

Application for quotation of securities - IMM

×

Application for quotation of securities - IMM

17 July 25

Change in substantial holding

×

Change in substantial holding

30 June 25

Change in substantial holding

×

Change in substantial holding

23 June 25

Update on Phase I Study of IMP761 for Autoimmune Diseases

×

Update on Phase I Study of IMP761 for Autoimmune Diseases

02 June 25

Immutep Corporate Presentation

×

Immutep Corporate Presentation

26 May 25

Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial

×

Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial

15 May 25

High Response Rates achieved in Lung Cancer in INSIGHT-003

×

High Response Rates achieved in Lung Cancer in INSIGHT-003

05 May 25

Excellent Overall Survival in Head & Neck Cancer Patients

×

Excellent Overall Survival in Head & Neck Cancer Patients

01 May 25

Change in substantial holding

×

Change in substantial holding

IMM Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.04 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -19.7 19.6 -18.5 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.04 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.03 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock 6.6 11.4 -39.9 Lock Lock Lock
     Yield % Lock Lock Lock Lock -12.6 -9.8 -17.8 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.11 0.13 0.10 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.11 0.12 0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 12.7 17.8 -25.1 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 901 1,201 1,456 Lock Lock Lock
Basic m Lock Lock Lock Lock 901 1,201 1,456 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -100.0 N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 43 48 68 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -8.9 -9.7 -5.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -43 -48 -68 Lock Lock Lock
     Growth % Lock Lock Lock Lock -18.1 -12.3 -40.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -45 -50 -70 Lock Lock Lock
     Growth % Lock Lock Lock Lock -17.1 -12.2 -39.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -40 -43 -61 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -40 -43 -61 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.9 -7.1 -43.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -35 -35 -62 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -21 -39 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 76 95 -1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -35 -35 -62 Lock Lock Lock
     Growth % Lock Lock Lock Lock -17.1 1.7 -78.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 123 182 130 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 147 202 157 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 1 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -122 -180 -128 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 11 12 13 Lock Lock Lock
Equity $m Lock Lock Lock Lock 136 190 144 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 138 191 144 Lock Lock Lock
     Growth % Lock Lock Lock Lock 43.8 38.8 -24.6 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -27.1 -21.2 -39.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -29.2 -22.5 -42.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -38.5 -30.7 -41.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -34.2 -26.0 -36.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -30.3 -21.2 -37.1 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Leverage
Interest Cover X Lock Lock Lock Lock -2,101.6 -1,573.4 -1,825.0 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.8 3.7 1.9 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -89.5 -95.1 -89.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 13.8 18.2 11.7 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 13.8 18.2 11.7 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 91.4 95.0 87.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -361.8 -332.1 -486.3 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -27.1 -21.2 -39.1 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -29.2 -22.5 -42.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -29.2 -22.5 -42.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 735.9 745.4 712.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -735.9 -745.4 -712.1 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

2.54%

Value ($M)

10

Prior Change

N/A

7 Day Change

-0.10%

1 Month Change

0.20%

3 Month Change

0.70%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IMM Shortsell

Frequently Asked Questions

The current share price of Immutep Ltd (IMM:ASX) is AU$0.3.
The 52-week high share price for Immutep Ltd (IMM:ASX) is AU$0.38.
The 52-week low share price for Immutep Ltd (IMM:ASX)? is AU$0.22.
Immutep Ltd (IMM:ASX) does not pay a dividend.
Immutep Ltd (IMM:ASX) does not pay a dividend.
Immutep Ltd (IMM:ASX) has a franking level of 0.0%.
Immutep Ltd (IMM:ASX) is classified in the Healthcare.
The current P/E ratio for Immutep Ltd (IMM:ASX) is .
The current share price of Immutep Ltd (IMM:ASX) is AU$0.3.
The 52-week high share price for Immutep Ltd (IMM:ASX) is AU$0.38.
The 52-week low share price for Immutep Ltd (IMM:ASX)? is AU$0.22.
Immutep Ltd (IMM:ASX) does not pay a dividend.
Immutep Ltd (IMM:ASX) does not pay a dividend.
Immutep Ltd (IMM:ASX) has a franking level of 0.0%.
Immutep Ltd (IMM:ASX) is classified in the Healthcare.
The current P/E ratio for Immutep Ltd (IMM:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox
App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.

Ff